The third quarter saw US Food and Drug Administration approvals for two anti-infectives. Pretomanid, indicated for drug-resistant tuberculosis (TB), is only the third TB drug approved over the past 50 years and the first antibiotic to be developed by a non-profit, the TB Alliance. Elsewhere, MSD Merck got the green light for Recarbrio, which is approved for intra-abdominal and for urinary and reproductive tract infections. Two new cancer drugs were approved through the agency’s accelerated approval pathway: Karyopharm’s Xpovio and Roche/Genentech’s Rozlytrek. In…
Drug pipeline 3Q19
The third quarter saw US Food and Drug Administration approvals for two anti-infectives. Pretomanid, indicated for drug-resistant tuberculosis (TB), is only the third TB drug approved over the past 50 years and the first antibiotic to be developed by a non-profit, the TB Alliance. Elsewhere, MSD Merck got the green light for Recarbrio, which is approved for intra-abdominal and for urinary and reproductive tract infections. Two new cancer drugs were approved through the agency’s accelerated approval pathway: Karyopharm’s Xpovio and Roche/Genentech’s Rozlytrek. In…